References
- “WHO Director-General’s opening remarks at the media briefing on COVID-19 – 11 March 2020.” [cited 2021 Sep 06]. Available from: https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19–-11-march-2020.
- Padhy BM, Mohanty RR, Das S, et al. Therapeutic potential of ivermectin as add on treatment in COVID 19: a systematic review and meta-analysis: ivermectin in COVID-19: a meta-analysis. J Pharm Pharm Sci. 2020;23:462–469.
- “DailyMed – STROMECTOL- ivermectin tablet.” [cited 2021 Sep 06]. Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=681888c9-af79-4b7d-ae80-c3f4f6f1effd.
- Caly L, Druce JD, Catton MG, et al. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020;178:104787.
- Popp M, et al. Ivermectin for preventing and treating COVID‐19. Cochrane Database Syst. Rev. 2021;(7):CD015017.
- PINHO AC. “EMA advises against use of ivermectin for the prevention or treatment COVID-19 outside randomised clinical trials,” European Medicines Agency. [updated 2021 Mar 19; cited 2021 Sep 06]. Available from: https://www.ema.europa.eu/en/news/ema-advises-against-use-ivermectin-prevention-treatment-covid-19-outside-randomised-clinical-trials.
- “HAN Archive - 00449 | Health Alert Network (HAN).” [updated 2021 Aug 26; cited 2021 Sep 06]. Available from: https://emergency.cdc.gov/han/2021/han00449.asp.
- “Therapeutics and COVID-19: living guideline.” [cited 2021 Sep 06]. Available from: https://www.who.int/publications-detail-redirect/WHO-2019-nCoV-therapeutics-2021.2.
- “Why You Should Not Use Ivermectin to Treat or Prevent COVID-19,” FDA, Sep. 2021. [cited 2021 Sep 06]. Available from: https://www.fda.gov/consumers/consumer-updates/why-you-should-not-use-ivermectin-treat-or-prevent-covid-19.
- “Ivermectin,” COVID-19 Treatment Guidelines. [cited 2021 Sep 06]. Available from: https://www.covid19treatmentguidelines.nih.gov/therapies/antiviral-therapy/ivermectin/.
- Lind JN, Lovegrove MC, Geller AI, et al. Increase in outpatient ivermectin dispensing in the US during the COVID-19 pandemic: a cross-sectional analysis. J Gen Intern Med. 2021;36(9):2909–2911.
- Chua K-P, Conti RM, Becker NV. US insurer spending on ivermectin prescriptions for COVID-19. JAMA. 2022;327(6):584.
- “ToxIC Forum – FACT Pharmacovigilance Project Sub-registry.” [cited 2021 Sep 06]. Available from: https://www.toxicregistry.org/FACT.html.
- Patridge EF, Bardyn TP. Research electronic data capture (REDCap). JMLA. 2018;106(1):142–144.
- “FAQ: COVID-19 and Ivermectin Intended for Animals,” FDA, Apr 2021. [cited 2021 Sep 06]. Available from: https://www.fda.gov/animal-veterinary/product-safety-information/faq-covid-19-and-ivermectin-intended-animals.
- “CVM Letter to Veterinarians and Retailers: Help Stop Misuse of Animal Ivermectin to Prevent or Treat COVID-19 in Humans,” FDA, Aug 2021. [cited 2021 Sep 06]. Available from: https://www.fda.gov/animal-veterinary/animal-health-safety-and-coronavirus-disease-2019-covid-19/cvm-letter-veterinarians-and-retailers-help-stop-misuse-animal-ivermectin-prevent-or-treat-covid-19.
- Chandler RE. Serious neurological adverse events after ivermectin-do they occur beyond the indication of onchocerciasis? Am J Trop Med Hyg. 2018;98(2):382–388.
- Bourguinat C, Kamgno J, Boussinesq M, et al. Analysis of the mdr-1 gene in patients co-infected with Onchocerca volvulus and Loa loa who experienced a post-ivermectin serious adverse event. Am J Trop Med Hyg. 2010;83(1):28–32.
- “National Poison Data System (NPDS) Bulletin COVID-19 (Ivermectin). American Association of Poison Control Centers.” [cited 2021 Sep 06]. Available from: https://www.aapcc.org/.
- Temple C, Hoang R, Hendrickson RG. Toxic effects from ivermectin use associated with prevention and treatment of covid-19. N Engl J Med. 2021;385:2197–2198.